


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1651034/publications.pdf Version: 2024-02-01



VAN VII

#	Article	IF	CITATIONS
1	Network-Based Pharmacology Study Reveals Protein Targets for Medical Benefits and Harms of Cannabinoids in Humans. Applied Sciences (Switzerland), 2022, 12, 2205.	2.5	1
2	Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1. Endocrinology, 2022, 163, .	2.8	1
3	Combined mass spectrometry-guided genome mining and virtual screening for acaricidal activity in secondary metabolites of <i>Bacillus velezensis</i> W1. RSC Advances, 2021, 11, 25441-25449.	3.6	8
4	A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 3821.	3.7	8
5	Abstract 3096: A novel ZIP4-NOTCH3-HDAC4 axis in ovarian cancer stem cells. , 2021, , .		0
6	An LC–MS/MS method for determination of O 6 â€benzylguanine and its metabolite O 6 â€benzylâ€8â€oxoguanine in human plasma. Biomedical Chromatography, 2020, 34, e4750.	1.7	0
7	GPR68 Is a Neuroprotective Proton Receptor in Brain Ischemia. Stroke, 2020, 51, 3690-3700.	2.0	20
8	A New Strategy of Overcoming both Matrix Effect and Shortage of Reference Standards for Determination of Multi-components in the Rhizomes of Alpinia officinarum Hance Using UHPLC-MS/MS with Single Exogenous Internal Standard. Food Analytical Methods, 2020, 13, 1867-1878.	2.6	2
9	5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i> -Mutant Colorectal Cancers. Cancer Research, 2020, 80, 4815-4827.	0.9	49
10	Unraveling the Molecular Mechanisms of Fructus Anisi Stellati as a Remedy for Infantile Colic by Network Pharmacology. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	1.2	5
11	ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 3692.	3.7	12
12	Anti-Helicobacter pylori-associated gastritis effect of the ethyl acetate extract of Alpinia officinarum Hance through MAPK signaling pathway. Journal of Ethnopharmacology, 2020, 260, 113100.	4.1	8
13	A Selective Fluorogenic Peptide Substrate for the Human Mitochondrial ATPâ€Dependent Protease Complex ClpXP. ChemBioChem, 2020, 21, 2037-2048.	2.6	2
14	A Proteolytic Siteâ€Directed Affinity Label to Inhibit the Human ATPâ€Dependent Protease Caseinolytic Complex XP. ChemBioChem, 2020, 21, 2049-2059.	2.6	0
15	Whole body deletion of Gpr68 does not change hematopoietic stem cell function. Stem Cell Research, 2020, 47, 101869.	0.7	1
16	Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside. Cancers, 2019, 11, 1523.	3.7	35
17	Onset of Telomere Dysfunction and Fusions in Human Ovarian Carcinoma. Cells, 2019, 8, 414.	4.1	3
18	Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion. Scientific Reports, 2019, 9, 4558.	3.3	13

#	Article	IF	CITATIONS
19	Analysis of oxygen-18 labeled phosphate to study positional isotope experiments using LC-QTOF-MS. Analytical Biochemistry, 2019, 566, 62-66.	2.4	1
20	Loss of Gpr68 Enhances Hematopoietic Stem Cell Function during Aging. Blood, 2019, 134, 3719-3719.	1.4	0
21	GPR68 Senses Flow and Is Essential for Vascular Physiology. Cell, 2018, 173, 762-775.e16.	28.9	205
22	Development and validation of an LC–MS/MS method for quantitative determination of GS87, a novel antineoplastic agent, in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 145-151.	2.8	1
23	Microwave-assisted enzymatic hydrolysis of DNA for mass spectrometric analysis: A new strategy for accelerated hydrolysis. Analytical Biochemistry, 2018, 546, 28-34.	2.4	7
24	RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clinical Cancer Research, 2018, 24, 1629-1643.	7.0	30
25	An LC–MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 189-198.	2.8	61
26	MAGEA1 inhibits the expression of BORIS via increased promoter methylation. Journal of Cell Science, 2018, 132, .	2.0	3
27	Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells. PLoS ONE, 2018, 13, e0197404.	2.5	8
28	Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment. Cancers, 2018, 10, 227.	3.7	38
29	Simultaneous determination of dihydrotestosterone and its metabolites in mouse sera by LC-MS/MS with chemical derivatization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1090, 22-35.	2.3	11
30	A rapid and sensitive LC–MS/MS method for quantitative analysis of cardiolipin (18:2)4 in human leukocytes and mouse skeletal muscles. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 386-394.	2.8	3
31	Determination of fatty acid methyl esters derived from algae <i>Scenedesmus dimorphus</i> biomass by GC-MS with one-step esterification of free fatty acids and transesterification of glycerolipids. Journal of Separation Science, 2017, 40, 2214-2227.	2.5	11
32	The emerging role of zinc transporters in cellular homeostasis and cancer. Signal Transduction and Targeted Therapy, 2017, 2, .	17.1	178
33	Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC–MS/MS. Biomedical Chromatography, 2017, 31, e3818.	1.7	1
34	Fucosylation Deficiency in Mice Leads to Colitis andÂAdenocarcinoma. Gastroenterology, 2017, 152, 193-205.e10.	1.3	48
35	The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget, 2017, 8, 90090-90107.	1.8	27
36	"LPA Regulates SOX9 in Ovarian Cancer Cells. Obstetrics & Gynecology Open Access, 2017, 1, .	0.0	2

#	Article	IF	CITATIONS
37	OGR1/GPR68 Modulates the Severity of Experimental Autoimmune Encephalomyelitis and Regulates Nitric Oxide Production by Macrophages. PLoS ONE, 2016, 11, e0148439.	2.5	15
38	The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines. Lipids, 2016, 51, 179-187.	1.7	8
39	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nature Communications, 2016, 7, 11971.	12.8	203
40	Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Research, 2016, 76, 3340-3350.	0.9	90
41	Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry. Biomedical Chromatography, 2015, 29, 1380-1387.	1.7	5
42	Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World Journal of Gastroenterology, 2015, 21, 7869.	3.3	23
43	The microenvironment reprograms circuits in tumor cells. Molecular and Cellular Oncology, 2015, 2, e969634.	0.7	3
44	FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer. Oncotarget, 2015, 6, 27688-27699.	1.8	40
45	Adoptive Transfer of Myeloid-Derived Suppressor Cells and T Cells in a Prostate Cancer Model. Bio-protocol, 2015, 5, .	0.4	0
46	DEVELOPMENT OF A LIQUID CHROMATOGRAPHIC METHOD FOR QUANTITATIVE DETERMINATION OF TRIAPINE, A RIBONUCLEOTIDE REDUCTASE INHIBITOR, BY SPECTROPHOTOMETRIC STUDY OF TRIAPINE COMPLEXATION REACTION. Journal of Liquid Chromatography and Related Technologies, 2014, 37, 1351-1372.	1.0	1
47	Mediatorless Immunoassay with Voltageâ€Controlled Intrinsic Amplification for Ultrasensitive and Rapid Detection of Microorganism Pathogens. ChemElectroChem, 2014, 1, 741-746.	3.4	2
48	Development and validation of LC–MS/MS method for quantitative determination of (â^')-securinine in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 19-26.	2.3	3
49	Reclaiming the Efficacy of β-Lactam–β-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime. Antimicrobial Agents and Chemotherapy, 2014, 58, 4290-4297.	3.2	35
50	Hypoxic conditions differentially regulate TAZ and YAP in cancer cells. Archives of Biochemistry and Biophysics, 2014, 562, 31-36.	3.0	30
51	The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Communication and Signaling, 2013, 11, 31.	6.5	119
52	Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression. Metabolomics, 2013, 9, 202-212.	3.0	19
53	Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production. Journal of Lipid Research, 2013, 54, 776-785.	4.2	55
54	Ovarian cancer G protein coupled receptor 1 suppresses cell migration of MCF7 breast cancer cells via a Gα <sub>12/13</sub> -Rho-Rac1 pathway. Journal of Molecular Signaling, 2013, 8, 6.	0.5	41

#	Article	IF	CITATIONS
55	Correction: The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Communication and Signaling, 2013, 11, 92.	6.5	0
56	Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers. PLoS ONE, 2013, 8, e57081.	2.5	18
57	The Lysophosphatidic Acid Receptor LPA <sub>1</sub> Promotes Epithelial Cell Apoptosis after Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 355-364.	2.9	110
58	Elevated and secreted phospholipase A <sub>2</sub> activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB Journal, 2012, 26, 3306-3320.	0.5	51
59	Response to Brosch etÂal Cell Metabolism, 2012, 15, 267-269.	16.2	5
60	From COX-2 inhibitor nimesulide to potent anti-cancer agent: Synthesis, inÂvitro, inÂvivo and pharmacokinetic evaluation. European Journal of Medicinal Chemistry, 2012, 47, 432-444.	5.5	53
61	Combination Therapy of an Inhibitor of Group VIA Phospholipase A2 with Paclitaxel Is Highly Effective in Blocking Ovarian Cancer Development. American Journal of Pathology, 2011, 179, 452-461.	3.8	22
62	Tumor cell group via phospholipase A <sub>2</sub> is involved in prostate cancer development. Prostate, 2011, 71, 373-384.	2.3	9
63	Group VIA phospholipase A <sub>2</sub> in both host and tumor cells is involved in ovarian cancer development. FASEB Journal, 2010, 24, 4103-4116.	0.5	58
64	An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples. Journal of Lipid Research, 2010, 51, 652-659.	4.2	133
65	Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Molecular Cancer Therapeutics, 2009, 8, 1692-1701.	4.1	42
66	Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3739-3742.	2.3	51
67	Quantitative Determination of Cannabinoid Receptor Antagonist Surinabant in Human Plasma by LC-UV and LC-ESI-MS/MS Methods. Journal of Liquid Chromatography and Related Technologies, 2009, 32, 2424-2436.	1.0	1
68	Lipid Generation and Signaling in Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 241-267.	0.5	5
69	Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for Ovarian Cancer G Protein-Coupled Receptor 1. PLoS ONE, 2009, 4, e5705.	2.5	77
70	S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Molecular Cancer Therapeutics, 2008, 7, 1993-2002.	4.1	57
71	Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 2696-2701.	1.6	174
72	Ovarian Cancer G Protein Coupled Receptor 1, a New Metastasis Suppressor Gene in Prostate Cancer. Journal of the National Cancer Institute, 2007, 99, 1313-1327.	6.3	81

#	Article	IF	CITATIONS
73	Lysophosphatidic Acid Is Constitutively Produced by Human Peritoneal Mesothelial Cells and Enhances Adhesion, Migration, and Invasion of Ovarian Cancer Cells. Cancer Research, 2006, 66, 3006-3014.	0.9	179
74	Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo. Cancer Research, 2006, 66, 7983-7990.	0.9	132
75	Caspase-3-dependent Activation of Calcium-independent Phospholipase A2 Enhances Cell Migration in Non-apoptotic Ovarian Cancer Cells. Journal of Biological Chemistry, 2006, 281, 29357-29368.	3.4	100
76	GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine. FASEB Journal, 2005, 19, 1-27.	0.5	64
77	A Simple and Quantitative Method for Analysis of Methoxyamine by Capillary Zone Electrophoresis. Journal of Liquid Chromatography and Related Technologies, 2005, 28, 2433-2443.	1.0	2
78	Determination of Genistein and Daidzein in Human Plasma by Liquid Chromatography and Tandem Mass Spectrometry. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 481-499.	1.0	7
79	Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 802, 263-270.	2.3	31
80	Biology of LPA in health and disease. Seminars in Cell and Developmental Biology, 2004, 15, 503-512.	5.0	67
81	Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1185-91.	2.5	143
82	A novel lamininâ€induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells. FASEB Journal, 2003, 17, 1-24.	0.5	75
83	Unfolding the Pathophysiological Role of Bioactive Lysophospholipids. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2003, 3, 23-32.	1.8	44
84	Unfolding the pathophysiological role of bioactive lysophospholipids. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2003, 3, 23-32.	1.8	33
85	ISOLATION AND QUANTITATION OF PLASMA LYSOPHOSPHATIDIC ACIDS BY SOLID-PHASE EXTRACTION AND CAPILLARY ELECTROPHORESIS. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 843-855.	1.0	10
86	Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1582, 81-88.	2.4	195
87	Lysophosphatidylcholine as a Ligand for the Immunoregulatory Receptor G2A. Science, 2001, 293, 702-705.	12.6	315
88	Electrospray Ionization Mass Spectrometry Analysis of Lysophospholipids in Human Ascitic Fluids: Comparison of the Lysophospholipid Contents in Malignant vs Nonmalignant Ascitic Fluids. Analytical Biochemistry, 2001, 290, 302-313.	2.4	220
89	Fatty Acid Composition of Lysophosphatidic Acid and Lysophosphatidylinositol in Plasma from Patients with Ovarian Cancer and Other Gynecological Diseases. Gynecologic Oncology, 2001, 83, 25-30.	1.4	66
90	Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nature Cell Biology, 2000, 2, 261-267.	10.3	269

#	Article	IF	CITATIONS
91	Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESIâ€MS) Analyses. Annals of the New York Academy of Sciences, 2000, 905, 242-259.	3.8	150
92	Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. FEBS Letters, 1999, 460, 513-518.	2.8	83
93	Capillary Electrophoresis. Analytical Chemistry, 1999, 71, 309-313.	6.5	16
94	Selective Determination of a Group of Organic Compounds in Complex Sample Matrixes by LC/MIMS with On-Line Immunoaffinity Extraction. Analytical Chemistry, 1998, 70, 931-935.	6.5	36
95	Michaelis-Menten Analysis of Alkaline Phosphatase by Capillary Electrophoresis Using Plug-Plug Reaction. Journal of Liquid Chromatography and Related Technologies, 1998, 21, 2781-2797.	1.0	25
96	Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers. JAMA - Journal of the American Medical Association, 1998, 280, 719.	7.4	570
97	Effect of lysophospholipids on signaling in the human Jurkat T cell line. Journal of Cellular Physiology, 1995, 163, 441-450.	4.1	82